My Profile

Search abstracts

Lewis Sheiner

Ljubljana, Slovenia

Stockholm, Sweden

Montreux, Switzerland

Budapest, Hungary

Lisboa, Portugal

Hersonissos, Crete, Greece

Alicante, Spain

Glasgow, Scotland

Venice, Italy

Athens, Greece

Berlin, Germany

St. Petersburg, Russia

Marseille, France

København, Denmark

Brugge/Bruges, Belgium

Pamplona, Spain

Uppsala, Sweden

Verona, Italy

Paris, France

Basel, Switzerland

Salamanca, Spain

Saintes, France

Wuppertal, Germany

Glasgow, Scotland

Sandwich, UK

Frankfurt, Germany

Greenford, UK

Paris, France

Basel, Switzerland

   Stockholm, Sweden

II-01 Åsa Kragh
Population pharmacokinetic analysis of PT010, an inhaled triple fixed-dose combination product, in patients with chronic obstructive pulmonary disease
Wednesday 15:10-16:40
II-02 Markus Krauß
Mice with human livers improve First-in-Human prediction of pharmacokinetics
Wednesday 15:10-16:40
II-03 Rukmini Kumar
Quantitative Systems Pharmacology (QSP) tools to aid in model development and communication: Vantage QSP Modeling Tools (VQM-Tools)
Wednesday 15:10-16:40
II-04 Hanna Kunina
Diabetes progression modelling of competing risks of long-term complications and mortality using Swedish registry data
Wednesday 15:10-16:40
II-05 Sofiene Laarif
Quantitative modeling of inter-lesion and inter-organ variability of tumor size
Wednesday 15:10-16:40
II-06 Jennifer Lang
Combining physiologically-based-pharmacokinetic modelling and a Bayesian method for prediction of ivabradine oral absorption and drug-drug interactions
Wednesday 15:10-16:40
II-07 Silvia Maria Lavezzi
Pharmacokinetic Models for Drug and Metabolites Including First Pass Effects: A Priori and A Posteriori Identifiability Analysis
Wednesday 15:10-16:40
II-08 Jean Lavigne
Population Pharmacokinetics of Piperacillin-Tazobactam Extended Infusions in Paediatric Population
Wednesday 15:10-16:40
II-09 Jacob Leander
Development of a population pharmacokinetic model of verinurad used for simulations of various dosing scenarios in different populations
Wednesday 15:10-16:40
II-10 Donghwan Lee
Effect of Pharmacokinetic Model Misspecification on Antibiotic Probability of Target Attainment Predicted by Monte Carlo Simulation
Wednesday 15:10-16:40
II-11 Woo Yul Lee
Population pharmacokinetics of recombinant coagulation factor VIII in Korean hemophila A patients
Wednesday 15:10-16:40
II-12 Soyoung Lee
Population Pharmacokinetic Analysis for Novel Acid Pump Antagonist DWP14012
Wednesday 15:10-16:40
II-13 Hyun A Lee
A mechanism-based pharmacokinetic/pharmacodynamic model to evaluate the mutual relationships between YH4808, a novel K+-competitive acid blocker, and intragastric pH in humans
Wednesday 15:10-16:40
II-14 So Jin Lee
The new era of pharmacokinetic/pharmacodynamic modeling and simulation in drug development in Korea
Wednesday 15:10-16:40
II-15 Anja Lehmann
Toxicokinetic modelling of hepatotoxic pyrrolizidine alkaloids: a combined in silico, in vitro and in vivo approach
Wednesday 15:10-16:40
II-16 Rory Leisegang
Establishing evidence for improved outcomes for HIV+ patients receiving antiretroviral drugs through home delivery
Wednesday 15:10-16:40
II-17 Giulia Lestini
Handling dropouts in longitudinal observational studies – an illustration of a workflow from data preparation to model building and model diagnostics in Alzheimer’s disease
Wednesday 15:10-16:40
II-18 Yisheng Li
A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling
Wednesday 15:10-16:40
II-19 Patrick Lilienthal
Mathematical modeling of RBC count dynamics after blood loss
Wednesday 15:10-16:40
II-20 Dan Liu
Investigating Impacts of Model Parameters Correlations in Global Sensitivity Analysis: Determining the most influential parameters of a Minimal PBPK Model of Midazolam
Wednesday 15:10-16:40
II-21 Feiyan Liu
Modeling inflammatory biomarker dynamics during clinical challenge studies with lipopolysaccharide
Wednesday 15:10-16:40
II-22 Carolina Llanos-Paez
Implementation of event time distribution as a random effect in time-to-event analysis
Wednesday 15:10-16:40
II-23 Rasmus Jansson Löfmark
Translational pharmacokinetic-pharmacodynamic modelling predicts human exposure target engagement
Wednesday 15:10-16:40
II-24 Aurelie Lombard
Tumour size measurements: impact of inter-operator variability on model-based drug effect evaluation
Wednesday 15:10-16:40
II-25 Dominik Lott
Prediction of exposure and effect on total lymphocyte count following long-term treatment of healthy subjects and lupus patients with the selective S1P1 receptor modulator cenerimod
Wednesday 15:10-16:40
II-26 Qiang Lu
Population Pharmacokinetic Meta-Analysis of Dupilumab in Adult Atopic Dermatitis Patients, Asthma Patients, and Healthy Subjects
Wednesday 15:10-16:40
II-27 Inga Ludwig
A Quantitative Approach to Assess Similarity of Adult and Pediatric Efficacy to Support Full or Partial Extrapolation in Pediatric Drug Development
Wednesday 15:10-16:40
II-28 Ulrich Ruben Luecht
Physiologically based pharmacokinetic modeling approach to assess drug-drug interactions (DDI) between psychopharmaceuticals – focus on mirtazapine and venlafaxine
Wednesday 15:10-16:40
II-29 Nicolas Luyckx
Improving the performances of clinical trial simulations in Simulo using compiled code
Wednesday 15:10-16:40
II-30 Yassine Kamal Lyauk
Dose Finding in Clinical Development of 60 FDA-Approved Drugs Compared to the Learning versus Confirming Paradigm
Wednesday 15:10-16:40
II-31 Sreenath M Krishnan
A combined population kinetic-pharmacodynamic-overall survival model for docetaxel and paclitaxel in the treatment of HER2–negative metastatic breast cancer patients
Wednesday 15:10-16:40
II-32 Guangda Ma
Evaluating the influence of genotype on warfarin dose predictions made using a theory-based PKPD model.
Wednesday 15:10-16:40
II-33 Panos Macheras
On the unphysical hypotheses in pharmacokinetics and oral drug absorption:Time to utilize instantaneous rate coefficients instead of rate constants
Wednesday 15:10-16:40
II-34 Paolo Magni
Artificial intelligence and machine learning: just a hype or a new opportunity for pharmacometrics?
Wednesday 15:10-16:40
II-35 Mats Magnusson
Population PK and PASI exposure-response modelling for Certolizumab pegol in patients with chronic plaque psoriasis
Wednesday 15:10-16:40
II-36 Corinna Maier
Quantifying the uncertainty: informative decision-support in individualised chemotherapy
Wednesday 15:10-16:40
II-37 Victor Mangas-Sanjuan
Population Pharmacokinetic and exposure-efficacy Markov modelling of enzymatic activity in Gaucher disease patients treated with enzyme replacement therapy
Wednesday 15:10-16:40
II-38 Nicolás Marco Ariño
Pharmacodynamic modelling of pupil diameter after noxious stimulus in patients undergoing surgery
Wednesday 15:10-16:40
II-39 Fatima Zahra Marok
Physiologically-based pharmacokinetic modeling of DPYD substrate 5-fluorouracil and its prodrug capecitabine
Wednesday 15:10-16:40
II-40 Frederico Martins
Application of Physiologically Based Pharmacokinetic (PBPK) Modelling to Support First in Human dose selection.
Wednesday 15:10-16:40
II-41 Paolo Mazzei
Prospective Evaluation of a Model-Based approach to select Phase 1 Dosing Regimen for MEN1309/OBT076, a novel antibody drug conjugate (ADC) targeting Ly75 antigen for the treatment of CD205-positive metastatic solid tumours and Non-Hodgkin lymphoma
Wednesday 15:10-16:40
II-42 Mark Meerson
Quantitative systems pharmacology model of key intraneuronal pathways regulating toxic protein accumulation in Alzheimer’s disease
Wednesday 15:10-16:40
II-43 Christophe Meille
Combining BLRM and safety PKPD models to improve decision making in a phase I dose escalation study: case study of PCA062, an antibody drug conjugate targeting P-Cadherin
Wednesday 15:10-16:40
II-44 Nicola Melillo
Global sensitivity analysis of a physiologically based pulmonary absorption model
Wednesday 15:10-16:40
II-45 France Mentré
New version of PFIM for optimal design in nonlinear mixed effects models using R S4
Wednesday 15:10-16:40
II-46 Matilde Merino-Sanjuán
Impact of ABC gene single nucleotide polymorphisms in population pharmacokinetic of capecitabine and its metabolites 5'-deoxy-5-fluorouridine (5'-DFUR) 5-fluorouracil (5-FU) in patients with colorectal cancer
Wednesday 15:10-16:40
II-47 Danica Michalickova
Pharmacokinetics of phenobarbital in neonates on extracorporeal membrane oxygenation
Wednesday 15:10-16:40
II-48 Robin Michelet
A workflow for application of the general pharmacodynamic interaction model on high-throughput combinatorial data in order to identify, quantify and characterise drug combinations that can overcome multi-drug-resistance
Wednesday 15:10-16:40
II-49 Iris Minichmayr
Impact of genetic variants of UGT1A1 on myelosuppression during irinotecan therapy
Wednesday 15:10-16:40
II-50 Jonathan Mochel
A Physiologically-Based Pharmacokinetic (PBPK) Model for the Prediction of Levodopa (L-dopa) Disposition in Plasma and Various Brain Compartments Across Species
Wednesday 15:10-16:40
II-51 Daniel Moj
Biotest’s Pentaglobin® in adults and neonates (term and preterm) – A PBPK approach
Wednesday 15:10-16:40
II-52 Camille Riff
Population Pharmacokinetics of Rituximab in patients with Chronic Lymphocytic Leukemia
Wednesday 15:10-16:40
II-53 Anna Mueller-Schoell
Model-informed precision dosing for tamoxifen therapy in breast cancer patients: Comparison of different target attainment metrics
Wednesday 15:10-16:40
II-54 Flora Musuamba Tshinanu
Dose optimization based on control and system theory: Case of Meropenem
Wednesday 15:10-16:40
II-55 Tadakatsu Nakamura
A Model-Based Meta-Analysis (MBMA) of Efficacy of Different Drugs for Postmenopausal Vasomotor-Symptoms
Wednesday 15:10-16:40
II-56 Ricardo Nalda-Molina
Evaluation of the predictive performance and the model adequacy of four population pharmacokinetic models of adalimumab in patients with inflammatory bowel disease.
Wednesday 15:10-16:40
II-57 Srividya Neelakantan
Population Pharmacokinetic/Pharmacodynamic Modeling of PF-06480605, an Anti-TL1A Antibody, in Healthy Subjects and Ulcerative Colitis Patients
Wednesday 15:10-16:40
II-58 Ida Netterberg
The tumor time-course predicts the overall survival in non-small cell lung cancer patients treated with atezolizumab in a large Phase I study: an evaluation of using different censoring times
Wednesday 15:10-16:40
II-59 Bernard Ngara
A Semi-mechanistic population pharmacokinetic model quantifying hair concentrations of ritonavir-boosted atazanavir. A study of HIV infected Zimbabweans adolescents.
Wednesday 15:10-16:40
II-60 Laurent Nguyen
Pharmacokinetic time-dependency and covariates modelling of Isatuximab monoclonal antibody in multiple myeloma patients: analysis from pooled phase I/II & phase III studies
Wednesday 15:10-16:40
II-61 Laura Zwep
Hierarchical group LASSO with random effects: identification of high-dimensional omics-drug interactions predictive of treatment response in patient-derived tumor growth data
Wednesday 15:10-16:40
II-62 Joakim Nyberg
Implicit and efficient handling of missing covariate information using full random effects modelling
Wednesday 15:10-16:40
II-63 Boram Ohk
Population pharmacokinetic analysis of tacrolimus: The role of integrative pharmacogenetics and pharmacometabolomics
Wednesday 15:10-16:40
II-64 Andrés Olivares-Morales
Bayesian pharmacokinetic (PK) and pharmacodynamic (PD) modelling of the qEEG response to a selective GABAA a5 receptor modulator in rats to inform its use as a translational biomarker
Wednesday 15:10-16:40
II-65 Sean Oosterholt
Model-based optimisation of N-acetylcysteine for the treatment of paracetamol overdose
Wednesday 15:10-16:40
II-66 Fernando Ortega
Developing a head and neck cancer model to assess the effect of radiotherapy on tumour growth inhibition and regrowth
Wednesday 15:10-16:40
II-67 Taniya Paiboonvong
Development of physiologically based pharmacokinetic model of sitafloxacin in plasma and epithelial lining fluid
Wednesday 15:10-16:40
II-68 Semra Palic
Neopterin dynamics in pediatric patients after miltefosine treatment of visceral leishmaniasis
Wednesday 15:10-16:40
II-69 Robert Palmér
A novel joint modelling approach to estimating treatment effects on COPD exacerbations in the presence of differential discontinuations
Wednesday 15:10-16:40
II-70 Hyeonsoo Park
A population pharmacokinetic model of Glimepiride(Amaryl®)
Wednesday 15:10-16:40
II-71 Christophe Passot
A kinetic-pharmacodynamic model of palbociclib reveals an influence of body weight on neutropenia onset.
Wednesday 15:10-16:40
II-72 Nathalie Perdaems
Translational PK-RO modelling for a mAb to predict the outcome of the first in human study
Wednesday 15:10-16:40
II-73 Carlos Perez-Ruixo
Exposure-response relationships of the efficacy and safety of apalutamide (APA) in men with non-metastatic castration-resistant prostate cancer (nmCRPC)
Wednesday 15:10-16:40
II-74 Soumya Perinparajah
Pharmacodynamics of rituximab on B cells in paediatric post-HSCT patients with EBV
Wednesday 15:10-16:40
II-75 Thomas Peyret
Development of a Quantitative Systems Pharmacology Model to Support Dosing of rhPTH(1-84), a Recombinant Human Parathyroid Hormone, in Adult Patients with Hypoparathyroidism
Wednesday 15:10-16:40
II-76 Chiara Piana
Development of a translational pharmacokinetic-biomarker-efficacy model in mouse to support dose recommendation in human
Wednesday 15:10-16:40
II-77 Philippe Pierrillas
PK-PD modelling of C4 concentrations after administration of a FXR agonist in healthy volunteers and Hepatitis B patients
Wednesday 15:10-16:40
II-78 Nikhil Pillai
Single objective genetic algorithm based approach for optimal population pharmacokinetic/pharmacodynamics (PK/PD) model selection for tumor growth response
Wednesday 15:10-16:40
II-79 Vikram Prabhakar
QSP Model of Rheumatoid Arthritis, capturing range of clinical responses to Methotrexate and anti-TNF-a therapies
Wednesday 15:10-16:40
II-80 Sudeep Pradhan
Evaluation of study designs to test the intact nephron hypothesis
Wednesday 15:10-16:40
II-81 Mélanie Prague
In Silico Clinical Trials for Evaluation of HIV Short-Cycle strategies
Wednesday 15:10-16:40
II-82 Luna Prieto Garcia
Physiologically-based pharmacokinetic model for itraconazole and its metabolites: the importance of parameter sensitivity analysis
Wednesday 15:10-16:40
II-83 Alicja Puszkiel
Population pharmacokinetic analysis of tamoxifen and its six metabolites in breast cancer patients: Quantification of the impact of genetic polymorphisms and co-medications on tamoxifen metabolism
Wednesday 15:10-16:40
II-84 Rajith Rajoli
PBPK Modelling of Atovaquone Long-acting Injectable Formulations
Wednesday 15:10-16:40
II-85 Chetan Rathi
Model-Informed selection of doses and sample size for a Phase 2a POC study of GSK3640254, a next generation HIV-1 maturation inhibitor
Wednesday 15:10-16:40
II-86 Michael Reed
Evaluation of competitive differentiation of novel therapies and the impact of patient variability on efficacy in a psoriasis QSP platform
Wednesday 15:10-16:40
II-87 Javier Reig-López
Validation of a Semi-mechanistic model with first-pass metabolism, two metabolic pathways and intestinal efflux transporter implemented in PhysPK biosimulation software.
Wednesday 15:10-16:40
II-88 Isabel Reinecke
Levonorgestrel-Containing Contraceptives: Comparison of Daily Doses and Exposure for Various Routes of Administration by an Integrated Population Pharmacokinetic Analysis
Wednesday 15:10-16:40
II-89 Dinko Rekic
Higher Febuxostat Exposure observed in Japanese Compared to Caucasian Subjects Independent of Bodyweight
Wednesday 15:10-16:40